Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › HRS9531-201 (NCT05881837)

HRS9531-201 (NCT05881837)

Ribupatide (HRS9531) · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Ribupatide (HRS9531)
Population
obesity
Phase
2
Participants
249
Duration
24 weeks
Registry
NCT05881837

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
1.0 mgobesity china24249—−5.4 % vs −0.1 %
Δ −5.3 pp
—2.0 vs 2.0—14.3 vs 8.26.1 vs 2.0——congress
3.0 mgobesity china24249—−13.4 % vs −0.1 %
Δ −13.3 pp
—2.0 vs 2.0—27.5 vs 8.219.6 vs 2.0——congress
4.5 mgobesity china24249—−14.0 % vs −0.1 %
Δ −13.9 pp
—0.0 vs 2.0—32.0 vs 8.220.0 vs 2.0——congress
6.0 mgobesity china24249—−16.8 % vs −0.1 %
Δ −16.7 pp
—0.0 vs 2.0—32.7 vs 8.228.6 vs 2.0——congress

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (16)
  • 1.0 mg · weight_tp · abstract
    in body weight was -5.4% (95% CI -7.3% to -3.5%), -13.4% (-15.2% to -
  • 1.0 mg · nausea · abstract
    Nausea 7 (14.3) 14 (27.5) 16 (32.0) 16 (32.7) 4 (8.2)
  • 1.0 mg · vomiting · abstract
    Vomiting 3 (6.1) 10 (19.6) 10 (20.0) 14 (28.6) 1 (2.0)
  • 1.0 mg · ae_dc · Table 3 (Adverse events), columns 1.0/3.0/4.5/6.0 mg/placebo
    1 (2.0) 1 (2.0) 0 0 1 (2.0)
  • 3.0 mg · weight_tp · abstract
    in body weight was -5.4% (95% CI -7.3% to -3.5%), -13.4% (-15.2% to -
  • 3.0 mg · nausea · abstract
    Nausea 7 (14.3) 14 (27.5) 16 (32.0) 16 (32.7) 4 (8.2)
  • 3.0 mg · vomiting · abstract
    Vomiting 3 (6.1) 10 (19.6) 10 (20.0) 14 (28.6) 1 (2.0)
  • 3.0 mg · ae_dc · Table 3 (Adverse events), columns 1.0/3.0/4.5/6.0 mg/placebo
    1 (2.0) 1 (2.0) 0 0 1 (2.0)
  • 4.5 mg · weight_tp · abstract
    11.5%), -14.0% (-15.9% to -12.1%), and -16.8% (-18.8% to -14.9%) in the
  • 4.5 mg · nausea · abstract
    Nausea 7 (14.3) 14 (27.5) 16 (32.0) 16 (32.7) 4 (8.2)
  • 4.5 mg · vomiting · abstract
    Vomiting 3 (6.1) 10 (19.6) 10 (20.0) 14 (28.6) 1 (2.0)
  • 4.5 mg · ae_dc · Table 3 (Adverse events), columns 1.0/3.0/4.5/6.0 mg/placebo
    1 (2.0) 1 (2.0) 0 0 1 (2.0)
  • 6.0 mg · weight_tp · abstract
    11.5%), -14.0% (-15.9% to -12.1%), and -16.8% (-18.8% to -14.9%) in the
  • 6.0 mg · nausea · abstract
    Nausea 7 (14.3) 14 (27.5) 16 (32.0) 16 (32.7) 4 (8.2)
  • 6.0 mg · vomiting · abstract
    Vomiting 3 (6.1) 10 (19.6) 10 (20.0) 14 (28.6) 1 (2.0)
  • 6.0 mg · ae_dc · Table 3 (Adverse events), columns 1.0/3.0/4.5/6.0 mg/placebo
    1 (2.0) 1 (2.0) 0 0 1 (2.0)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: HRS9531-201 (NCT05881837). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs9531-201/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.